Sealing the left atrial appendage: Ready for prime time?

American Journal of the Medical Sciences

Volumn 333, Issue 5, 2007, Pages 285-289

  El Chami, Mikhael F ^a   Hoffman, Mathew ^a   Lerakis, Stamatios ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Left atrial appendage occlusion; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; POLYMER; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEVICE; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART LEFT ATRIUM; HEART SURGERY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LEFT ATRIUM APPENDAGE OCCLUSION DEVICE; LIGATION; OCCLUSIVE CEREBROVASCULAR DISEASE; RISK REDUCTION; SCORING SYSTEM; STROKE; THROMBOSIS PREVENTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

EID: 34249057251     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3180533bfb     Document Type: Review

References (31)

1. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1067-78.
2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
3. Ostermayer S, Reschke M, Billinger K, et al. Percutaneous closure of the left atrial appendage. J Interv Cardiol 2003;16:553-6.
4. Porebska A, Nowacki P. [Atrial fibrillation as a relevant risk factor for stroke]. Neurol Neurochir Pol 2005;39:134-40.
5. Frost L, Engholm G, Johnsen S, et al. Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. Am J Med 2000;108:36-40.
6. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
7. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
8. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-9.
9. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354.
10. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
11. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995;26:1471-7.
12. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4.
13. Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001;86:569-74.
14. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors: Stroke Prevention In Reversible Ischemia Trial (SPIRIT): European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319-27.
15. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-53.
16. Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003;60:417-22.
17. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999;82:547-54.
18. Stoddard MF. Risk of thromboembolism in new onset or transient atrial fibrillation. Prog Cardiovasc Dis 1996;39:69-80.
19. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998;128:639-47.
20. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation: Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998;31:1622-6.
21. Garcia-Fernandez MA, Perez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003;42:1253-8.
22. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association: Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 1998;32:1486-588.
23. Nakai T, Lesh MD, Gerstenfeld EP, et al. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation 2002;105:2217-22.
24. Barbato G, Carinci V, Pergolini F, et al. Percutaneous occlusion of the left atrial appendage for systemic embolism prevention in patients with atrial fibrillation: state of the art and report of two cases. Ital Heart J 2005;6:409-13.
25. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887-9.
26. Omran H, Hardung D, Schmidt H, et al. Mechanical occlusion of the left atrial appendage. J Cardiovasc Electrophysiol 2003;14:S56-9.
27. Hanna IR, Kolm P, Martin R, et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J Am Coll Cardiol 2004;43:1868-72.
28. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multicenter feasibility trials. J Am Coll Cardiol 2005;46:9-14.
29. Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006;151:956-61.
30. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151.
31. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004;10:S451-58; discussion S458-61.